1. Furthermore, the premature termination of the “aliskirin trial in type 2 diabetes using cardiovascular and renal disease endpoints” (ALTITUDE) trial which tested the dual blockade of the renin-angiotensin-aldosterone (RAAS) system and aliskirin plus angiotensin conversion enzyme (ACE) inhibitor or sartan, has been relined by published data.